Novartis at India Supreme Court: Evergreening Myths and Patent Reality

Patently BIOtech

Novartis will go before India’s Supreme Court on September 11, 2012 challenging the refusal by the Indian Patent Office to grant a patent on its cancer drug Glivec.  The Indian Patent Office rejected Novartis’ application under a provision in Indian law which is aimed at guarding against so called “patent evergreening.” BIO has written two posts deconstructing the myth of patent evergreening.


Globalism Pictures

1.  Patent “Ever-Greening”: Novartis Confronts Patent Myth in India

2.  Patent Evergreening in India: Response from the Other Side

While patent evergreening may be a myth, the need for incentives to develop new and better treatments and cures for patients is very real. Patents are a crucial incentive for innovators to conduct clinical trials, meet regulatory requirements, and launch their treatments and cures around the world.

Patently BIOtech  |  Email This Post  |  Printer Friendly
Tags: , , , ,

Leave a Reply

Your email address will not be published. Required fields are marked *

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>